Deep Dive: Page 2
Industry insights from our journalists
-
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease.
Ned Pagliarulo • May 21, 2018 -
After a flurry, NASH deals put on pause
After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature.
Lisa LaMotta • May 21, 2018 -
NASH drug pipeline headed toward uncertain market
The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity.
Jacob Bell • May 21, 2018 -
3 market-busting hurdles to NASH commercialization
With the first NASH drugs expected to win approval over the next two to three years, drugmakers will face several major barriers to market entry.
Lisa LaMotta • May 21, 2018 -
Oncology boom spurs DTC advertising, and with it controversy
As the debate for and against direct-to-consumer advertising rages on, cancer drugmakers look poised to pump massive amounts of money into the practice.
Jacob Bell • May 16, 2018 -
Lilly's JAK woes set the stage for AbbVie, Gilead to jump ahead
An adcomm's iffy stance on baricitinib could mean one less thing to worry about for rivals looking to break into the fairly open JAK inhibitor market.
Jacob Bell • April 24, 2018 -
As India, China drug industries mature, FDA scrutiny an overhang
Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D.
Ned Pagliarulo • April 23, 2018 -
CAR-T ups challenges in pharma supply chain
New technology made it viable to ship the cell therapies. Now, stakeholders are pushing for more innovation to meet looming commercial demands.
Jacob Bell • April 23, 2018 -
Two years after cancer setback, Bristol-Myers' new biomarker bet pays off
The success of CheckMate-227 is a step toward validating tumor mutational burden, but questions remain about how easily the test could be adopted.
Ned Pagliarulo • April 16, 2018 -
I/O combos inch forward in pharma's lung cancer quest
An impressive survival benefit could lift Merck's Keytruda plus chemo regimen, while Bristol-Myers hopes its checkpoint inhibitor pairing can help it catch up.
Ned Pagliarulo • April 16, 2018 -
Gene therapy heavyweights talk next steps for CAR-T
Several big names in cell and gene therapy development discussed what's on the horizon at a meeting of the Alliance for Cancer Gene Therapy.
Lisa LaMotta • April 11, 2018 -
Abuse deterrents still finding their niche in the pain space
Hard-to-abuse opioids haven't been on the market for very long, and whether they have staying power amid a public health crisis remains an open question.
Jacob Bell • March 26, 2018 -
Lilly's bet on pain stands out amid bare pharma pipeline
Even as the opioid epidemic has heightened the need for non-addictive painkillers, few pharma companies have made pain a therapeutic area of focus.
Ned Pagliarulo • March 26, 2018 -
Incyte study could bring lessons for cancer immunotherapy
Merck has bet on the potential of Incyte's IDO blocker as a partner for Keytruda across five different cancer types. A Phase 3 trial in melanoma is first up.
Ned Pagliarulo • March 14, 2018 -
Despite crowded I/O field, pharma, VCs still eager to invest
Surging biopharma investment into cancer has raised concerns about duplicative research. Industry execs, however, see the opportunities as too great to pass up.
Ned Pagliarulo • March 09, 2018 -
For Cosentyx, Taltz, Siliq: A marketing race to differentiate
The IL-17 arena is getting pretty crowded, pushing drugmakers to explore various routes to market dominance.
Jacob Bell • March 07, 2018 -
Pharma taking liberties with DTC ads, says study
A new study analyzes current DTC ad campaigns and dissects whether disclosure of beneficial side effects could be misleading or interpreted as off-label promotion.
Randi Hernandez • March 07, 2018 -
Numbers show drugmakers are keeping RTFs under wraps
A BioPharma Dive analysis of company and FDA data show plenty of companies are not disclosing Refusal to File letters from the FDA.
Lisa LaMotta • March 05, 2018 -
Pharma moves beyond Seres hangover in microbiome space
While there have been no major acquisitions of microbiome-focused companies, early research has attracted a wealth of big pharma dollars.
Lisa LaMotta • Feb. 26, 2018 -
Cancer and the microbiome: What's old is new again
A healthy gut may improve how well cancer patients respond to immunotherapy. A big unanswered question is why.
Ned Pagliarulo • Feb. 26, 2018 -
The (still somewhat mysterious) science behind the microbiome
Though nascent, microbiome research is offering valuable insights about how tiny organisms improve — and threaten — human health.
Jacob Bell • Feb. 26, 2018 -
Hunting for the 'good' and 'bad' bacteria in the microbiome
Research into the trillions of bacteria living in the gut has surged, boosting interest in developing diagnostics.
Suzanne Elvidge • Feb. 26, 2018 -
CAR-T growing up with big pharma's big bet
Major acquisitions by Celgene and Gilead should catalyze further investment into the technology needed to make CAR-T work smoothly. Yet cell therapy's commercial potential remains an open question.
Ned Pagliarulo • Feb. 20, 2018 -
Ramaswamy has no regrets about Axovant
The CEO says he wouldn't change a thing, despite the high-profile failure and sharp decline of the company.
Lisa LaMotta • Feb. 13, 2018 -
What Gilead taught pharma about pricing a cure
With Sovaldi in the rearview mirror and gene therapies progressing quickly, the industry is debating what lessons can be learned about pricing a cure.
Lisa LaMotta • Feb. 12, 2018
Previous
